A Study of A-101 Solution in Subjects With Common Warts.
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Solution in Subjects With Common Warts.
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Pennsylvania
-
Wayne、Pennsylvania、美国、19087
- Aclaris Therapeutics, Inc.
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Subject is at least 18 years of age
- Subject has a clinical diagnosis of common warts
Subject has 1 appropriate Target Wart as defined below, on the trunk or extremities:
- Have a longest axis that is 3mm to 10mm
- Have a thickness ≤3mm
- Be a discrete lesion
- Be, when centered in the circular cutout of the provided template, the only common wart present
- Not be periungual, subungual, genital or anal
- Not be covered with hair which, in the Investigator's opinion, would interfere with the study medication treatments or the study evaluations Not be in an area that may be occluded (by clothing, footwear or within a skin fold).
- The Target Wart has a Physician Wart Assessment (PWA) ≥2
- If the subject is a woman of childbearing potential, she has a negative urine pregnancy test and agrees to use an approved effective method of birth control for the duration of the study
- Subject is non-pregnant and non-lactating
- Subject is in good general health and free of any known disease state or physical condition which, in the Investigator's opinion, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations
- Subject is willing and able to follow all study instructions and to attend all study visits
- Subject is able to comprehend and willing to sign an Informed Consent Form.
Exclusion Criteria:
- Subject has clinically atypical warts on the trunk or extremities
- Subject is immune compromised (due to chemotherapy, systemic steroids, genetic immunodeficiency, transplant status, etc.)
- Subject has a history of Human Immunodeficiency Virus (HIV) infection
- Subject has had any Human Papilloma Virus (HPV) vaccine within 1 year prior to enrollment
Subject has used any of the following intralesional therapies within the specified period prior to enrollment to the Target Wart:
- Immunotherapy (Candida antigen, mumps antigen, Trichophyton antigen);
- Anti-metabolite therapy (bleomycin, 5-fluorouracil)
Subject has used any of the following systemic therapies within the specified period prior to enrollment:
- Immunomodulatory/immunosuppressant therapy (e.g., etanercept, alefacept, infliximab);
- Glucocortico-steroids (inhaled and intra-nasal steroids are permitted);
Subject has used any of the following topical therapies within the specified period prior to enrollment on, or in a proximity to the Target Wart, which in the Investigator's opinion, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations:
- LASER (pulsed-dye laser), light (intense pulsed light, photo-dynamic therapy, other energy based therapy); Immuno-therapy ( imiquimod, squaric acid dibutyl ester, etc.); Anti-metabolite therapy (5-fluorouracil); Retinoids; Liquid nitrogen, electrodesiccation, curettage; Over-the-counter wart therapies
Subject has had any of the following within the specified period prior to enrollment on, or in a proximity to the target lesion, which in the Investigator's opinion, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations:
- A cutaneous malignancy;
- A pre-malignancy (actinic keratosis)
- Subject has a history of sensitivity to any of the ingredients in the study medications
- Subject has any current skin disease (psoriasis, atopic dermatitis, eczema, sun damage, etc.), skin condition (sunburn, open wounds) or other disease or condition (uncontrolled diabetes) which, in the Investigator's opinion, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations
- Subject has participated in an investigational drug trial in which administration of an investigational study medication occurred within 30 days prior to enrollment.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:A-101 Solution 40
A-101 Solution 40% administered once per week
|
|
实验性的:A-101 Solution 45
A-101 Solution 45% administered once per week
|
|
安慰剂比较:Vehicle Solution
Vehicle Solution administered once per week
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Efficacy Based on Mean Change in Physician Wart Assessment Over Time
大体时间:57 Days
|
The primary effectiveness will consist of the mean change from Visit 2 to Visit 10 in Physician Wart Assessment (PWA) performed using Analysis of Covariance (ANCOVA) with Visit 2 PWA as the covariate.
Physician Wart Analysis is a measurement scale from 0 to 3 that evaluates the wart with 0 being clear and 3 being clinically diagnosable wart that is raised, with an obviously rough surface.
|
57 Days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Durability of Response - Percentage of Participants That Were Clear at Visit 10 That Are Still Clear at Visit 13
大体时间:visit 10 to visit 13
|
Percentage of subjects whose target wart was clear at Visit 10 and who remained clear at Visit 13 for active treatment groups
|
visit 10 to visit 13
|
PWA Responder
大体时间:Day 57
|
The percentage of participants who were responders with the target wart judged to be clear (PWA = 0) at Visit 10.
|
Day 57
|
合作者和调查者
调查人员
- 研究主任:Stuart D Shanler, MD、Aclaris Therapeutics, Inc.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
A-101 Solution 40的临床试验
-
Applied Molecular Transport完全的